4.4 Review

A ride through the epigenetic landscape: aging reversal by reprogramming

Journal

GEROSCIENCE
Volume 43, Issue 2, Pages 463-485

Publisher

SPRINGER
DOI: 10.1007/s11357-021-00358-6

Keywords

Epigenetics; Aging; Reprogramming; Rejuvenation

Funding

  1. EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine [EP/L015838/1]
  2. AstraZeneca
  3. Diamond Light Source
  4. Defence Science and Technology Laboratory
  5. Evotec
  6. GlaxoSmithKline
  7. Janssen
  8. Novartis
  9. Pfizer
  10. Syngenta
  11. Takeda
  12. UCB
  13. Vertex

Ask authors/readers for more resources

This review explores the interplay between epigenetics and aging, with a focus on the potential of epigenetic reprogramming for age reversal. While in vivo partial reprogramming holds promise as a therapy, there are several limitations that need to be addressed. Reprogramming for rejuvenation is a young but rapidly expanding subfield in the biology of aging.
Aging has become one of the fastest-growing research topics in biology. However, exactly how the aging process occurs remains unknown. Epigenetics plays a significant role, and several epigenetic interventions can modulate lifespan. This review will explore the interplay between epigenetics and aging, and how epigenetic reprogramming can be harnessed for age reversal. In vivo partial reprogramming holds great promise as a possible therapy, but several limitations remain. Rejuvenation by reprogramming is a young but rapidly expanding subfield in the biology of aging.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available